FoundationOne Liquid is the first and only liquid biopsy test to show prospective clinical utility in a global, registrational trial for patients with newly diagnosed, metastatic non-small cell lung cancer (NSCLC).1 Learn more about FoundationOne Liquid
Foundation Medicine, The Molecular Information Company, is connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands.
Better Care Today
Comprehensive Genomic Profiling
Our portfolio of genomic tests is the leading platform for comprehensive genomic profiling. We analyze more than 300 cancer-relevant genes across the four main classes of genomic alterations to help understand the genomic makeup of a patient's tumor.
Valuable Insights, Actionable Options
We help match each patient’s unique genomic profile to known targeted therapies, immunotherapies and clinical trials and offer decision support services, financial assistance, and technology solutions to help streamline patient care.
Dealing with cancer is not just dealing with the cancer. It’s treating the whole person.
Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test.
Better Care Tomorrow
More Than Numbers
Insights, Not Just Information
Our unique knowledgebase, FoundationCore™, is one of the world's largest cancer genomic databases, with more than 300,000 anonymized patient records, designed to help researchers and biopharma companies advance precision medicine, develop new therapies, and design better trials.
Supporting Drug Development
The Preferred Partner to BioPharma
We partner with drug developers throughout each stage of drug research and development,
from target discovery to commercial launch. Today, we are working with more than 30
biopharma partners to accelerate new biomarker-driven treatments.
Advancing Cancer Care
Each patient’s cancer informs all those cases that will come in the future.
Learn more about our recent Journal of the American Medical Association (JAMA) publication on our clinico-genomic database (CGDB) that demonstrates how real-world clinico-genomic data obtained during the course of routine patient care can yield scientifically and clinically meaningful insights.
Gaurav Singal, MD, Chief Data Officer
Better Care Together
The Power of Collaboration
By sharing our genomic data, we empower researchers on the front lines to generate new connections and insights. Today, we proudly participate in a number of sharing initiatives to accelerate research efforts.
Transforming Cancer Care
Cultivating an Ecosystem of Partners
Every insight we gain towards better cancer care is multiplied by a hyper-connected network of physicians, biopharma, researchers, patient advocacy organizations and world-leading medical centers. Together, we are transforming cancer care.
From the Blog
As scientists worldwide continue to pioneer breakthroughs and change the way we understand and treat advanced cancer, it’s important to stay connected so we can learn from one another. The annual European Society for Medical Oncology (ESMO) Congress is one such opportunity for the cancer community to share the latest developments in oncology research and reflect on how far we’ve come.
Join Us in the Pursuit of Better
1 LBA81_PR ‘Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: initial results from ALK+ cohort’ will be presented by Shirish Gadgeel during the proffered paper session on Monday, 30 September 2019, 08:30-10:00 CEST in Madrid Auditorium (Hall 2). Annals of Oncology, Volume 30, Supplement 5, October 2019.